Five Prime Therapeutics, Inc. (FPRX) Given Consensus Recommendation of “Hold” by Brokerages
Shares of Five Prime Therapeutics, Inc. (NASDAQ:FPRX) have earned an average rating of “Hold” from the ten analysts that are presently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $66.25.
A number of analysts recently issued reports on FPRX shares. Zacks Investment Research lowered Five Prime Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, May 2nd. Jefferies Group LLC reiterated a “buy” rating and issued a $55.00 price target on shares of Five Prime Therapeutics in a report on Thursday, June 8th. ValuEngine upgraded Five Prime Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, June 2nd. Finally, BidaskClub lowered Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 2nd.
Hedge funds have recently bought and sold shares of the company. Creative Planning raised its stake in Five Prime Therapeutics by 0.8% in the second quarter. Creative Planning now owns 6,744 shares of the biotechnology company’s stock worth $203,000 after buying an additional 54 shares in the last quarter. Laurion Capital Management LP bought a new stake in Five Prime Therapeutics during the first quarter worth $210,000. Rockefeller Financial Services Inc. bought a new stake in Five Prime Therapeutics during the second quarter worth $210,000. BlueCrest Capital Management Ltd bought a new stake in Five Prime Therapeutics during the first quarter worth $254,000. Finally, Arxis Securities LLC bought a new stake in Five Prime Therapeutics during the first quarter worth $267,000. Institutional investors own 85.10% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece was published by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/08/11/five-prime-therapeutics-inc-fprx-given-consensus-recommendation-of-hold-by-brokerages.html.
Shares of Five Prime Therapeutics (NASDAQ:FPRX) traded up 4.55% during midday trading on Friday, reaching $27.83. The company had a trading volume of 348,917 shares. The stock has a 50-day moving average of $29.56 and a 200 day moving average of $34.86. Five Prime Therapeutics has a 52 week low of $25.97 and a 52 week high of $60.98. The firm’s market capitalization is $777.71 million.
Five Prime Therapeutics (NASDAQ:FPRX) last announced its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($1.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.15) by $0.43. The firm had revenue of $7.80 million during the quarter, compared to analysts’ expectations of $8.32 million. Five Prime Therapeutics had a negative net margin of 356.39% and a negative return on equity of 31.78%. The firm’s revenue for the quarter was down 16.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.49) EPS. On average, analysts anticipate that Five Prime Therapeutics will post ($5.10) earnings per share for the current year.
About Five Prime Therapeutics
Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.
Receive News & Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.